As of Jun 22
| +0.10 / +2.39%|
The 2 analysts offering 12-month price forecasts for Caladrius Biosciences Inc have a median target of 11.00, with a high estimate of 15.00 and a low estimate of 7.00. The median estimate represents a +157.01% increase from the last price of 4.28.
The current consensus among 2 polled investment analysts is to Buy stock in Caladrius Biosciences Inc. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.